NDAORALTABLET, EXTENDED RELEASE
Approved
Feb 2006
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
6/8 — Strong
CLARINEX-D 12 HOUR (desloratadine and pseudoephedrine sulfate) by Merck & Co. is histamine h1 receptor antagonists [moa]. Approved for histamine-1 receptor antagonist [epc]. First approved in 2006.
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CLARINEX-D 12 HOUR is an oral extended-release combination tablet containing desloratadine (a selective histamine H1-receptor antagonist) and pseudoephedrine sulfate (a decongestant). It is indicated for the relief of symptoms associated with seasonal allergic rhinitis in adults and children 12 years and older. The desloratadine component blocks histamine-mediated allergic responses while pseudoephedrine reduces nasal congestion.
$0.764MPart D
LOE ApproachingDeclining
Product approaching loss of exclusivity with minimal Part D spend signals a mature, declining brand requiring defensive commercial strategies and reduced team investment.
Mechanism of Action
Histamine H1 Receptor Antagonists
Pharmacologic Class:
Histamine-1 Receptor Antagonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Bioequivalence Study of Desloratadine and Pseudoephedrine Sulfate Extended-release Tablets Under Fasting Conditions
Started Apr 2006
34 enrolled
Healthy
Career Relevance
Zero linked job openings reflect the product's mature, declining commercial status and minimal current hiring activity at Merck for this franchise. Career growth opportunities are limited; professionals working on this product typically support maintenance of existing market position rather than launch or expansion initiatives.
Company
Worked on CLARINEX-D 12 HOUR at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.